Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
NCT06636071Phase 3Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setrusumab in osteogenesis imperfecta (OI), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures at 24 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT06636071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636071.